Trials / Terminated
TerminatedNCT04462055
Effectiveness of Dupilumab in Food Allergic Patients With Moderate to Severe Atopic Dermatitis
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3 (actual)
- Sponsor
- UMC Utrecht · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effectiveness of Dupilumab in food allergic patients with moderate to severe Atopic Dermatitis (AD). Included patients participated in the BioDay Registry.
Detailed description
The positive results of the dupilumab studies in AD, asthma and nasal polyposis with chronic sinusitis validate the fundamental role for IL-4 and IL-13 in the pathogenesis of these diseases, and add to the possibility that these cytokines are also critically involved in other related allergic/atopic (type 2 immune) diseases that are often co-morbidly associated with AD, such as food allergy.
Conditions
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2022-07-01
- Completion
- 2022-07-01
- First posted
- 2020-07-08
- Last updated
- 2022-07-29
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04462055. Inclusion in this directory is not an endorsement.